Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.
about
Protecting the normal in order to better kill the cancerPhase II study to topotecan and cisplatin in advanced hepatocellular carcinoma.Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administrationThe bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitorA phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignanciesPerspectives on biologically active camptothecin derivatives.Anticancer Alkaloids from Trees: Development into Drugs.CRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Camptothecin in Clinical DevelopmentPreclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.Potent antiviral activity of topoisomerase I and II inhibitors against Kaposi's sarcoma-associated herpesvirusTopoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.Inhibition of retrovirus-induced disease in mice by camptothecin.A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumoursCancer therapies utilizing the camptothecins: a review of the in vivo literatureSingle-antibody, targeted nanoparticle delivery of camptothecin.A series of alpha-amino acid ester prodrugs of camptothecin: in vitro hydrolysis and A549 human lung carcinoma cell cytotoxicity.Tumour-selective targeting of drug metabolizing enzymes to treat metastatic cancerSemisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives.Topoisomerase I inhibitors and drug resistanceIdentification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.Semi-quantitative analysis of DNA topoisomerase-I mRNA level using reverse transcription-polymerase chain reaction in cancer cell lines: its relation to cytotoxicity against camptothecin derivative.Soluplus--solubilized citrated camptothecin--a potential drug delivery strategy in colon cancer.Current perspectives on camptothecins in cancer treatmentA novel preparation method for camptothecin (CPT) loaded folic acid conjugated dextran tumor-targeted nanoparticles.Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines.CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer.Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.Topoisomerases as anticancer targets.Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.Camptothecin induces G2/M phase arrest through the ATM-Chk2-Cdc25C axis as a result of autophagy-induced cytoprotection: Implications of reactive oxygen species.Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
P2860
Q26801291-CF747698-E72C-42B3-B580-F4B909D9CA8DQ33349102-459F1B5A-2D82-4CB7-88C5-F00CED3BB8B8Q33361186-4894550D-F992-4DB4-A385-B2547A573435Q33495553-1826FCC3-5425-40A2-955B-8FFC512D0366Q33500497-56EF7B6A-94DE-4052-9A49-AB9D52873681Q33504409-7C21C7DB-1A0D-45D2-92CD-004CEECB3FB9Q34327123-49C11702-BAB9-4837-9022-EDF903A9F1C6Q34468628-20006095-D732-4219-B74B-47DE32804F1FQ34549113-E778B668-79C0-4255-B815-6CDE7572FF70Q35237593-8EE3C459-C4C3-4D1B-A094-D5C5B4154419Q35631349-6864ED22-CA73-4773-B683-8396D62F53AAQ35689364-61A521E7-EADB-4FC5-B3E7-4D5439CCC1ADQ36431807-A22C12CA-9D04-46CA-8835-3E35A759240AQ36624086-93B28953-E2C6-483C-9193-B1E3733FCD96Q36648965-11FB506B-BC69-4939-83BE-FFDD277686B4Q36694292-A03BF9FF-3B97-4A8F-BA58-AEAFB3175327Q37069556-B16EADA9-4060-424A-9624-464DA43DECFCQ37227392-7FC565B1-2137-4207-B1B5-B37598EA1E71Q37512130-FAA066B3-9876-4D9E-955F-1D3C86A171E7Q38898663-2E280924-9905-47BF-94BA-174DF77820D7Q39777927-0C7EC9B2-D28F-4C92-95CD-FBC75EDCA9D8Q40028536-A217EFAA-FFDE-4974-8083-1FEA13675296Q40876335-148D8EE5-5CC5-415C-8E62-66458923F0AEQ41453174-AF1C8247-3D26-4B5B-A6EC-4D1C5E7BB8B8Q42174340-411429C5-E6D9-44EB-80C1-5278AD81D13DQ42715927-EFE7D839-00BE-4DFA-BB39-C5FEC7991E03Q42865967-097C1A64-654F-4E3F-BC17-1BD7225AD6F7Q43201995-7D59B1BD-ECB0-4F67-BFFE-4B1C57E1A8C1Q43827787-E01BA2F5-4D2C-4901-8B80-40F7182218F7Q47139613-EC472D98-519D-442C-87A8-2604F7F30343Q47220295-7455DFEA-E1F0-49E5-AF87-C283FF239C2BQ49164024-0594C2EF-4FCB-42CA-A861-9628871DC81EQ49164031-9F909114-A462-4B73-B81F-9B35B8E133E6Q49832269-35F8BA2F-4006-4B80-A790-3A96DA76B56CQ52507148-955408CD-FE4E-49B8-AB11-D617043ED686Q54167076-5A62F697-C96E-4276-86BD-CC4B06298A94Q54978825-9AC5BFA3-6180-4C91-9DFA-C5CBAF06BA1EQ54982736-5C5574FA-37A0-4337-965D-8FCBD9C52C8F
P2860
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.
description
1972 nî lūn-bûn
@nan
1972 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1972 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1972年の論文
@ja
1972年論文
@yue
1972年論文
@zh-hant
1972年論文
@zh-hk
1972年論文
@zh-mo
1972年論文
@zh-tw
1972年论文
@wuu
name
Phase I clinical trial of week ...... tion with preclinical studies.
@ast
Phase I clinical trial of week ...... tion with preclinical studies.
@en
type
label
Phase I clinical trial of week ...... tion with preclinical studies.
@ast
Phase I clinical trial of week ...... tion with preclinical studies.
@en
prefLabel
Phase I clinical trial of week ...... tion with preclinical studies.
@ast
Phase I clinical trial of week ...... tion with preclinical studies.
@en
P2093
P1476
Phase I clinical trial of week ...... ation with preclinical studies
@en
P2093
H H Hansen
O S Selawry
P J Creaven
P304
P577
1972-08-01T00:00:00Z